P. Kellokumpu-Lehtinen, “Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: Is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy – results from a ra”, AO, vol. 46, no. 2, pp. 146–152, Jan. 2007.